Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.69
+0.06003.68%
Post-market: 1.720.0300+1.78%19:57 EST
Volume:3.96M
Turnover:6.72M
Market Cap:379.79M
PE:-1.73
High:1.75
Open:1.66
Low:1.63
Close:1.63
52wk High:3.78
52wk Low:0.8621
Shares:224.73M
Float Shares:168.00M
Volume Ratio:0.43
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9781
EPS(LYR):-1.3222
ROE:-54.43%
ROA:-27.34%
PB:1.20
PE(LYR):-1.28

Loading ...

Allogene Therapeutics to Participate in Citi Virtual Oncology Leadership Summit and TD Cowen Health Care Conference

Reuters
·
Feb 05

Allogene CFO Geoffrey M. Parker Reports Sale of Common Shares

Reuters
·
Feb 05

Allogene Therapeutics EVP of R&D Zachary Roberts Reports Disposal of Common Shares

Reuters
·
Feb 05

January 2026 Penny Stock Spotlight: Three Promising Picks

Simply Wall St.
·
Jan 12

Allogene Therapeutics Up Over 20%, on Pace for Largest Percent Increase Since February 2025 -- Data Talk

Dow Jones
·
Jan 10

Cellectis SA Outlines 2026 Strategy with Focus on Advancing Pivotal Phase 2 CAR-T Trials, Presenting Key Clinical Data, and Expanding Strategic Partnerships

Reuters
·
Jan 09

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Jan 09

Allogene outlines 2026 as program-defining year for allogeneic CAR T

TIPRANKS
·
Jan 08

BRIEF-Allogene Therapeutics Interim Futility Analysis Of Mrd Clearance From Phase 2 Alpha3 Trial Planned For Early Q2 2026

Reuters
·
Jan 08

Allogene Therapeutics Inc - Proof-of-Concept for Allo-329 Slated by End of H1 2026

THOMSON REUTERS
·
Jan 08

Allogene Therapeutics Inc - Interim Futility Analysis of Mrd Clearance From Phase 2 Alpha3 Trial Planned for Early Q2 2026

THOMSON REUTERS
·
Jan 08

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Benzinga_recent_news
·
Dec 17, 2025

Allogene Wins Arbitration, Retains Full Control of Cema-Cel Rights

Reuters
·
Dec 16, 2025

Cellectis Wins Partial Victory in Arbitration Against Servier Over License Agreement

Reuters
·
Dec 16, 2025

Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Disposal of Common Shares

Reuters
·
Nov 20, 2025

Key Market Intelligence on November 12th, how much did you miss?

Blockbeats
·
Nov 12, 2025

Coinbase Delays ALLO Spot Trading Launch

Blockbeats
·
Nov 12, 2025

OKX will list ALLO-USD perpetual contract

Blockbeats
·
Nov 12, 2025

ALLO opened at $0.9887, now trading at $0.79.

Blockbeats
·
Nov 11, 2025

Binance to List ALLO 1-50x Upside Perpetual Contract

Blockbeats
·
Nov 11, 2025